PROJECT HELIX – DUAL-REVENUE PHARMA PLATFORM | $2M GROWTH ROUND @ $6.67M PRE

The Angle: Founder-operated pharma play with live revenue ($1.7M) and $5M inventory already banked—your dollar one goes to growth, not R&D roulette. Business Model: OTC Line: Two launched brands (UK/US) with clinical differentiation—~95% mineral bioavailability, cognitive health validation. Distribution across 5,000+ pharmacy doors. Line 2: 23 proprietary dossiers targeting underserved indications. 8 already filed. Regional approval timelines = faster monetization than global pharma cycles. Cap Table & Use of Funds: $2M raise for 30% (implies $6.67M pre) Proceeds: founder liquidity, OTC brand acceleration, working capital Clean structure. Prior exit to regional pharma incumbent = operational credibility. Unit Economics & Projections: Current EBITDA: $800K (47% margin—rare at this stage) 2026E EBITDA: $890K 2030E EBITDA: $67M (assumes Rx approvals convert + OTC scale) Exit Thesis: IPO within 5 years. $1B+ valuation predicated on pharma comps (8–12x EBITDA) + pipeline optionality. Why This Works: Most early pharma = binary bets on clinical trials. This is revenue today + optionality tomorrow. The $5M finished goods inventory de-risks your entry—essentially pre-funded scale with no manufacturing lag. Rx pipeline is structured as 23 separate shots on goal, not one all-or-nothing Phase III. Risk Consideration: Regulatory approval timelines (even regional) carry execution risk. OTC margin compression if brand spend doesn't convert###-###-#### projections assume aggressive Rx conversion—stress-test downside. Comparable Context: Regional pharma M&A multiples sitting at 10–15x EBITDA. If even half the Rx pipeline clears and OTC holds margin, you're looking at 8–12x entry multiple expansion by exit. Next Step: Full teaser + model available via redacted Worth a deeper dive if you're allocating to healthcare with near-term cash visibility.